Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ORGANIZATION
ORGANIZATION
- Clinical Trial Environment Must Match Global Standards, Says JPMA Evaluation Chief
September 2, 2025
- Information Provisioning on Solo Channels Is Duty of Both Makers and Wholesalers: JPMA Distribution Chief
September 1, 2025
- Indicators Needed to Frame Pharma as Growth Market in Japan, Says JPMA Policy Chief
August 29, 2025
- Wage Hikes Average in Low 4% Range, Similar to Last Year: Pharma Labor Group
August 28, 2025
- Victims’ Group Urges Stronger Safety Measures amid New Drug Modalities
August 27, 2025
- Hemp Cannabinoid Consortium Draws 40 Inquiries from Industry and Academia
August 22, 2025
- JMA Slams Idea of Scrapping Insurance Coverage for OTC-Like Drugs
August 8, 2025
- Japan Needs New Pricing Scheme for Regenerative Medicine: Industry Group
July 31, 2025
- Japan Society Poised to Set Out Criteria to Standardize Regional Formularies, Eyes August Release
July 31, 2025
- Takeda Alumni Link with Osaka Biz Lobby to Support Drug Discovery
July 28, 2025
- JPMA Urges Safeguards for Patient Access in Any Future Drug Tariff Talks
July 24, 2025
- JPMA Selected for Japan Program to Cut Carbon Emissions
July 23, 2025
- Industry Calls for More Tailored Govt Support on Drug Loss Product Development
July 16, 2025
- Japan Logs 11th Straight Year of Decline in Drug Reps, Voluntary Buyouts Likely a Major Factor
July 16, 2025
- Japan’s Generic Use Rate Reaches 86.5% in FY2024: JGA
July 7, 2025
- FPMAJ Confirms Regulatory Compliance Actions Completed for All Generic Drug Discrepancies
July 3, 2025
- Pharma Labor Platform Calls for Inflation-Responsive Drug Pricing Reforms, Opposes CEA Expansion
July 3, 2025
- Japan’s Contract Rep Ratio Hits Record as Biotechs, Foreign Firms Drive Demand
July 1, 2025
- FPMAJ Chair Questions Sakigake as Incentive for Prioritizing Japan R&D
June 24, 2025
- JGA Targets FY2027 for Resolving Drug Shortages, Two Years Ahead of Forecast
June 20, 2025
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…